The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis

• Conditions: reumatism; rheumatoid arthritis; 10023213

• Registration Number: NL-OMON32522
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 261

Inclusion Criteria

1) RA diagnosis according to ACR criteria
2) been treated adequately with one of the anti-TNF alpha agents with insufficient effects;
3) a moderate to high disease activity (DAS28 > 3.2)

Exclusion Criteria

1) former treatment with abatacept or rituximab.
2) patient's or physician's preference for one of the agents
3) contraindications

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary outcomes are the DAS28 at 12 months, quality adjusted life years and<br /><br>societal costs over 12 months. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcomes are the health assessment questionnaire, the short-form 36,<br /><br>time to failure and the percentage of patients crossing over to another<br /><br>treatment. </p><br>